A Phase 4 interventional study of Dorzolamide / Timolol Ophthalmic Solution and dorzolamide/timolol in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Laboratorios Poen. Completed at 6 sites in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.
Sponsored by Laboratorios Poen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing dorzolamide in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. dorzolamide · Glaucoma, Open-Angle.
Among the 14 studies testing dorzolamide in Glaucoma, Open-Angle, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 12 in phase 4, and was the 13th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 14 studies testing dorzolamide in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →
dorzolamide: first FDA approval 1994 (TRUSOPT). What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2 · Phase 4 12
First in 1999; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 74 across the 14 interventional studies. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 14 have an industry lead sponsor. The 10 most frequent:
Laboratorios Poen is the lead sponsor of 4 studies on the registry; none are open to participants now.
Laboratorios Poen has 2 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing dorzolamide in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved ophthalmic formulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glaucotensil TD LC, Laboratorios Poen
Drug: Dorzolamide / Timolol Ophthalmic Solution
Glaucotensil TD, Laboratorios Poen
Drug: dorzolamide/timolol
Drug pages: Dorzolamide · Timolol
Dorzolamide-timolol fixed combination in a preservative-free multidose device
Also known as: Glaucotensil TD LC
Drug pages: Dorzolamide · Timolol
Dorzolamide-timolol BAK-preserved fixed combination
Also known as: Glaucotensil TD
Ocular Surface Disease Symptoms
OSDI questtionarie
Time frame: Change from baseline in OSDI score at 24 weeks
Intraocular preassure
Intraocular preassure (PIO) by GAT
Time frame: Change from baseline in PIO (mmHg) at 24 weeks
Break-up Time
Break-up Time (BUT)
Time frame: Change from baseline BUT (seconds) at 24 weeks
SCHIRMER-ITEST
Schirmer test without anesthesia
Time frame: Change from baseline Shirmer test (mm) at 24 weeks
Conjunctival Hyperemia
Conjunctival Hyperemia
Time frame: Change from baseline in porcentaje of patients with conjunctival hyperemia at 24 weeks
Satisfaction questionnaire
Satisfaction questionnaire
Time frame: Change from baseline of patient satisfaction at 24 weeks using a 5-point likert scale
Best corrected visual acuity
snellen scale 20/20
Time frame: Change from baseline visual acuity at 24 weeks
Treatment preference
Treatment preference
Time frame: Treatment preference with respect previous treatment at Week 24
Superficial corneal epithelium density
Superficial corneal epithelium density analyzed by confocal microscopy expresed by cells /mm2
Time frame: Change from baseline superficial corneal epithelium density at 48 weeks
Basal corneal epithelium density
Basal corneal epithelium density analyzed by confocal microscopy expresed by cells /mm2
Time frame: Change from baseline basal corneal epithelium density at 48 weeks
Corneal Estroma reflectivity
Corneal Estroma reflectivity analyzed by confocal microscopy expresed by 5-point scale of grade
Time frame: Change from baseline in the grade of corneal estroma reflectivity at 48 weeks specify by 4 grade scale reported by Martone et al. .
Corneal nerve density
Corneal nerve density analyzed by confocal microscopy expresed by cells /mm2
Time frame: Change from baseline corneal nerve density at 48 weeks
Neuroma density
Neuroma density analyzed by confocal microscopy expresed by neuromas/mm2
Time frame: Change from baseline neuroma density at 48 weeks
Dendrite density
Dendrite density analyzed by confocal microscopy expresed by dendrites/mm2
Time frame: Change from baseline dendrite density at 48 weeks
Corneal nerve tortuosity
Corneal nerve tortuosity analyzed by confocal microscopy expresed by 5-point scale of grade
Time frame: Change from baseline in the grade of corneal nerve tortousity at 48 weeksusing a 5 point scale reported by Oliviera-Soto et al.
Endothelial cell density
endothelial cell density analyzed by confocal microscopy expresed by cells/mm2
Time frame: Change from baseline endothelial cell count at 48 weeks
Conjuctival epithelium density
Conjuntival epithelium density analyzed by confocal microscopy expresed by cells/mm2
Time frame: Change from baseline conjuctival epithelium density at 48 weeks
Goblett cell density
Goblett cell density nalyzed by confocal microscopy expresed by cells/mm2
Time frame: Change from baseline goblett cell density at 48 weeks
Inflamatory infiltrates
Description of presence or absence of inflamtory cells on conjuntiva
Time frame: Change from baseline in inflamatory infiltrates at 48 weeks
Ran from Mar 2023 to primary completion in Nov 2024, 19 months.
Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dorzolamide · Timolol
Laboratorios Poen